+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Specialty Generics Market by Product Type (Biosimilar, Small Molecule), Drug Delivery System (Inhalation, Injectables, Oral), Molecule Type, Disease Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Specialty Generics Market by Product Type (Biosimilar, Small Molecule), Drug Delivery System (Inhalation, Injectables, Oral), Molecule Type, Disease Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Specialty Generics Market by Product Type (Biosimilar, Small Molecule), Drug Delivery System (Inhalation, Injectables, Oral), Molecule Type, Disease Indication, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012051
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The specialty generics market is swiftly reshaping the global pharmaceutical landscape, forging critical pathways for affordable, advanced therapies. Senior decision-makers face an evolving ecosystem that demands agility, as technological breakthroughs, shifting regulations, and new market pressures define strategy and opportunity.

Market Snapshot: Specialty Generics Market Size and Growth Trajectory

The specialty generics market grew from USD 93.56 billion in 2024 to USD 103.78 billion in 2025. It is expected to continue expanding at a CAGR of 10.83%, achieving USD 173.44 billion by 2030. This robust growth reflects rising demand for biosimilars and complex small molecule generics as healthcare systems prioritize cost containment and expanded patient access. As both established and emerging markets embrace advanced therapies, supply chain resilience and innovation remain fundamental competitive levers for stakeholders across the spectrum.

Scope & Segmentation of the Specialty Generics Market

This report delivers a comprehensive analysis, helping leaders pinpoint high-potential niches and establish defensible positions across the industry value chain. Key segmentation points include:

  • Product Type: Includes biosimilars (monoclonal antibodies and recombinant proteins), as well as small molecule generics (injectables in pre-filled syringes and vials, liquid and solid oral dosage forms).
  • Drug Delivery System: Encompasses inhalation, injectables, oral, and topical drug delivery approaches, each presenting unique stability, adherence, and logistics challenges.
  • Molecule Type: Covers biologics such as monoclonal antibodies and recombinant proteins, alongside chemical entity-based generics.
  • Disease Indication: Addresses targets in autoimmune conditions, hormonal disorders, and oncology.
  • Distribution Channel: Includes hospital pharmacies, online pharmacies, and retail pharmacies, each shaping accessibility and purchasing behaviors.
  • Regional Scope: Examines key markets in the Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East, and Africa (notably United Kingdom, Germany, France, Russia, Italy, Spain, UAE, South Africa, and more), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, and others).
  • Key Players: Features company analysis for Sandoz International GmbH, Teva Pharmaceutical Industries, Fresenius Kabi AG, Viatris Inc., Pfizer Inc., Hikma Pharmaceuticals, Dr. Reddy’s Laboratories, Baxter International, Amneal Pharmaceuticals, and Apotex Inc.

Key Takeaways for Senior Decision-Makers

  • Rapid advances in manufacturing technologies, such as continuous processing and precision bioprocessing, are enhancing efficiency and reducing production timelines for specialty generics.
  • Regulatory frameworks and streamlined approval pathways are enabling wider adoption of biosimilars, helping to intensify market competition and broaden patient access.
  • Growing focus on personalized medicine and patient-centric models drives innovation in drug delivery systems, such as tailored oral and injectable formulations.
  • Strategic collaborations between pharmaceutical innovators, technology providers, and contract manufacturing organizations support enhanced supply chain integration and accelerated go-to-market strategies.
  • Investments in clinical evidence generation and real-world data analytics boost payer confidence, supporting differentiated value propositions and reimbursement models.
  • Targeted regional manufacturing and distribution alliances are crucial for navigating diverse regulatory and economic environments across multiple geographies.

Tariff Impact: Navigating U.S. Trade Policy on Specialty Generics

Recent U.S. tariffs have introduced new supply chain complexities, especially regarding imported active pharmaceutical ingredients (APIs). In response, manufacturers are reevaluating sourcing strategies, forging long-term partnerships with domestic API producers or establishing regional hubs in tariff-exempt zones. While these changes improve resilience, they also demand capital investment and operational adjustments. Industry collaborations and policy advocacy are supporting efforts to secure tariff exemptions for vital therapeutic ingredients—critical for market stability amid evolving trade landscapes.

Methodology & Data Sources

The research draws on in-depth interviews with senior executives, regulatory specialists, and clinicians, supported by quantitative market analysis from proprietary and secondary sources. Expert panels reviewed all findings, ensuring methodological rigor, trend triangulation, and scenario testing under diverse market conditions.

Why This Report Matters for Strategic Planning

  • Facilitates targeted portfolio expansion by clarifying technology shifts, supply chain risks, and regulatory nuances across key segments and geographies.
  • Empowers leaders to anticipate and respond to operational disruptions, emerging tariff impacts, and shifting stakeholder demands with actionable insights.
  • Supports evidence-based decision-making for investment prioritization, partnership selection, and market entry or expansion strategies.

Conclusion

The specialty generics market is defined by rapid evolution and multidimensional growth drivers. This analysis equips senior leaders to proactively address emerging risks, harness new opportunities, and achieve sustainable competitive advantage in a dynamic global landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of advanced drug delivery technologies to improve bioavailability of specialty generics
5.2. Regulatory alignment challenges in global approval pathways for oncology generic biologics
5.3. Market entry strategies for high-value orphan disease generics amid limited competition
5.4. Impact of major patent expirations on revenue projections for specialty biologic generics
5.5. Integration of digital health tools to support patient adherence for specialty generic therapies
5.6. Pricing negotiations and rebate dynamics in hospital procurement of specialty generics
5.7. Development of high-concentration injectable formulations to reduce administration volume challenges
5.8. Collaboration models between CDMOs and pharmaceutical companies for niche specialty generic development
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Specialty Generics Market, by Product Type
8.1. Introduction
8.2. Biosimilar
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.3. Small Molecule
8.3.1. Injectables
8.3.1.1. Pre-Filled Syringes
8.3.1.2. Vials
8.3.2. Liquid Oral Dosage Forms
8.3.3. Solid Oral Dosage Forms
9. Specialty Generics Market, by Drug Delivery System
9.1. Introduction
9.2. Inhalation
9.3. Injectables
9.4. Oral
9.5. Topical
10. Specialty Generics Market, by Molecule Type
10.1. Introduction
10.2. Biologic
10.2.1. Monoclonal Antibodies
10.2.2. Recombinant Proteins
10.3. Chemical Entity
11. Specialty Generics Market, by Disease Indication
11.1. Introduction
11.2. Autoimmune
11.3. Hormonal Disorders
11.4. Oncology
12. Specialty Generics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Specialty Generics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Specialty Generics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Specialty Generics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Sandoz International GmbH
16.3.2. Teva Pharmaceutical Industries Limited
16.3.3. Fresenius Kabi AG
16.3.4. Viatris Inc.
16.3.5. Pfizer Inc.
16.3.6. Hikma Pharmaceuticals PLC
16.3.7. Dr. Reddy’s Laboratories Limited
16.3.8. Baxter International Inc.
16.3.9. Amneal Pharmaceuticals, Inc.
16.3.10. Apotex Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SPECIALTY GENERICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. SPECIALTY GENERICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. SPECIALTY GENERICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. SPECIALTY GENERICS MARKET: RESEARCHAI
FIGURE 26. SPECIALTY GENERICS MARKET: RESEARCHSTATISTICS
FIGURE 27. SPECIALTY GENERICS MARKET: RESEARCHCONTACTS
FIGURE 28. SPECIALTY GENERICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SPECIALTY GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SPECIALTY GENERICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY LIQUID ORAL DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY LIQUID ORAL DOSAGE FORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SOLID ORAL DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SOLID ORAL DOSAGE FORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CHEMICAL ENTITY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY CHEMICAL ENTITY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY GENERICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 113. CANADA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. CANADA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. CANADA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 116. CANADA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 117. CANADA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 118. CANADA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 119. CANADA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 120. CANADA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 121. CANADA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 122. CANADA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 123. CANADA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 124. CANADA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 125. CANADA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 126. CANADA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 127. CANADA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. CANADA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. MEXICO SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 134. MEXICO SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 135. MEXICO SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 136. MEXICO SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 137. MEXICO SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 138. MEXICO SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 139. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 140. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 141. MEXICO SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 144. MEXICO SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 145. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. MEXICO SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. GERMANY SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 224. GERMANY SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 225. GERMANY SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 226. GERMANY SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 227. GERMANY SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 228. GERMANY SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 229. GERMANY SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 230. GERMANY SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 231. GERMANY SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 232. GERMANY SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 233. GERMANY SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 234. GERMANY SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 235. GERMANY SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 236. GERMANY SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 237. GERMANY SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 238. GERMANY SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 239. GERMANY SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. GERMANY SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. FRANCE SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. FRANCE SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. FRANCE SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 244. FRANCE SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 245. FRANCE SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 246. FRANCE SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 247. FRANCE SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 248. FRANCE SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 249. FRANCE SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 250. FRANCE SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 251. FRANCE SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 252. FRANCE SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 253. FRANCE SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 254. FRANCE SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 255. FRANCE SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 256. FRANCE SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 257. FRANCE SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. FRANCE SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. ITALY SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 278. ITALY SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 279. ITALY SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 280. ITALY SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 281. ITALY SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 282. ITALY SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 283. ITALY SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 284. ITALY SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 285. ITALY SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 286. ITALY SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 287. ITALY SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 288. ITALY SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 289. ITALY SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 290. ITALY SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 291. ITALY SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 292. ITALY SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 293. ITALY SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. ITALY SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. SPAIN SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. SPAIN SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. SPAIN SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 298. SPAIN SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 299. SPAIN SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 300. SPAIN SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 301. SPAIN SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 302. SPAIN SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 303. SPAIN SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 304. SPAIN SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 305. SPAIN SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 306. SPAIN SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 307. SPAIN SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 308. SPAIN SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 309. SPAIN SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 310. SPAIN SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 311. SPAIN SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 312. SPAIN SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY DRUG DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY BIOLOGIC, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES SPECIALTY GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 332. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 334. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 336. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 338. SAUDI ARABIA SPECIALTY GENERICS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 339. SA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Specialty Generics market report include:
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Limited
  • Fresenius Kabi AG
  • Viatris Inc.
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Limited
  • Baxter International Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 103.78 Billion
Forecasted Market Value ( USD ) by 2030 $ 173.44 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Buccal Drug Delivery Systems Market by Product Type (Films, Gels, Patches), Drug Class (Analgesics, Cardiovascular, Central Nervous System), Application, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Buccal Drug Delivery Systems Market by Product Type (Films, Gels, Patches), Drug Class (Analgesics, Cardiovascular, Central Nervous System), Application, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Drug Delivery System Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Drug Delivery System Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 86 Pages
  • Global
From
Novel Drug Delivery Systems Market by Route Of Administration (Inhalation, Injectable, Nasal), Technology (Hydrogels, Implants, Microneedles), Application, Product Type, End User - Global Forecast 2025-2030 - Product Image

Novel Drug Delivery Systems Market by Route Of Administration (Inhalation, Injectable, Nasal), Technology (Hydrogels, Implants, Microneedles), Application, Product Type, End User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Electronic Drug Delivery Systems Market Report 2025 - Product Image

Electronic Drug Delivery Systems Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Electronic Drug Delivery Systems Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Electronic Drug Delivery Systems Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.